Targeted Radionuclide Therapy is an evolving and promising modality of cancer treatment
add
remove
Targeted Therapies
Lutetium-177 is a medical radioisotope being investigated for therapies targeting advanced prostate, breast, melanoma, lung, pancreatic, and neuroendocrine cancers.
“Theranostic” Advantages
add
remove
Beta-particles (490 keV) from β− decay provide therapy within a very short range in soft tissue (1.7 mm max), while low-energy gammas (113 keV, 208 keV) are suitable for diagnostic imaging purposes.
Optimal Half-Life
add
remove
Half-life of 6.7 days is helpful for synthesis and transport while allowing for quick elimination from the body.
Significant Demand Growth
add
remove
Projected to be the most applied therapeutic radioisotope by 2023.
TARGETED RADIONUCLIDE THERAPY
ADVANCED TECHNOLOGY
MEDICAL RADIOISOTOPES
Please rotate your device.
This site can be viewed in landscape mode on mobile devices or on any computer.
